Matthew Moschner sold $1.6M of CGNX
CEO & President at COGNEX CORP. 24,962 shares at an average of $64.01, traded Aug 11, 2026, filed Aug 12, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.6M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002054688-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | MOption exercise Common Stock10b5-1 | +1,600 | $56.44 | $90k | 20,846 | Aug 12, 2026 |
| Aug 11, 2026 | SOpen-market sale Common Stock10b5-1 | -1,600 | $65.36 | $105k | 19,246 | Aug 12, 2026 |
| Aug 11, 2026 | MOption exercise Common Stock10b5-1 | +4,000 | $51.49 | $206k | 23,246 | Aug 12, 2026 |
| Aug 11, 2026 | SOpen-market sale Common Stock10b5-1 | -4,000 | $65.36 | $261k | 19,246 | Aug 12, 2026 |
| Aug 11, 2026 | MOption exercise Common Stock10b5-1 | +4,000 | $40.71 | $163k | 23,246 | Aug 12, 2026 |
| Aug 11, 2026 | SOpen-market sale Common Stock10b5-1 | -4,000 | $63.62 | $254k | 19,246 | Aug 12, 2026 |
| Aug 11, 2026 | MOption exercise Common Stock10b5-1 | +7,000 | $42.84 | $300k | 26,246 | Aug 12, 2026 |
| Aug 11, 2026 | SOpen-market sale Common Stock10b5-1 | -7,000 | $63.61 | $445k | 19,246 | Aug 12, 2026 |
| Aug 11, 2026 | SOpen-market sale Common Stock10b5-1 | -8,362 | $63.62 | $532k | 10,884 | Aug 12, 2026 |
| Aug 11, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 11, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -7,000 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 11, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 11, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -1,600 | $0.00 | $0 | 0 | Aug 12, 2026 |
Related signals
Other insiders at COGNEX CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | CGNXsell COGNEX CORP | Darren Marc Long Vice President | $1.3M 20,252 shares | -201% | |
| 53Moderate | COGNEX CORP | Laura Ann Macdonald VP and PAO | $9.3M 139,722 shares | -991% | |
| 53Moderate | COGNEX CORP | Mark Fennell Chief Legal Officer &Secretary | $4.3M 64,873 shares | -576% | |
| 60Notable | COGNEX CORP | Dianne M Parrotte director | $2.4M 44,000 shares | -122% | |
| 37Weak | COGNEX CORP | Carl Gerst EVP, Global Sales and Products | $802k 14,336 shares | -166% | |
| 60Notable | COGNEX CORP | Joerg Kuechen Head of Corporate M&A | $3.5M 61,900 shares | -450% | |
| 33Weak | COGNEX CORP | Angelos Papadimitriou director | $231k 4,150 shares | -20% | |
| 26Weak | COGNEX CORP | Robert Willett CEO & President | $128k 2,148 shares | -100% | |
| 40Moderate | COGNEX CORP | Robert Willett CEO & President | $10M 177,052 shares | -102% | |
| 38Weak | COGNEX CORP | Laura Ann Macdonald VP and PAO | $851k 14,881 shares | -324% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.